Your browser doesn't support javascript.
loading
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Postel-Vinay, Sophie; Lam, Vincent K; Ros, Willeke; Bauer, Todd M; Hansen, Aaron R; Cho, Daniel C; Stephen Hodi, F; Schellens, Jan H M; Litton, Jennifer K; Aspeslagh, Sandrine; Autio, Karen A; Opdam, Frans L; McKean, Meredith; Somaiah, Neeta; Champiat, Stephane; Altan, Mehmet; Spreafico, Anna; Rahma, Osama; Paul, Elaine M; Ahlers, Christoph M; Zhou, Helen; Struemper, Herbert; Gorman, Shelby A; Watmuff, Maura; Yablonski, Kaitlin M; Yanamandra, Niranjan; Chisamore, Michael J; Schmidt, Emmett V; Hoos, Axel; Marabelle, Aurelien; Weber, Jeffrey S; Heymach, John V.
Afiliação
  • Postel-Vinay S; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France sophie.postel-vinay@gustaveroussy.fr.
  • Lam VK; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ros W; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Bauer TM; Sarah Cannon Research Institute, Nashville, Tennessee, USA.
  • Hansen AR; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Cho DC; New York Medical College, Valhalla, New York, USA.
  • Stephen Hodi F; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Schellens JHM; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Litton JK; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Aspeslagh S; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.
  • Autio KA; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Opdam FL; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • McKean M; Sarah Cannon Research Institute, Nashville, Tennessee, USA.
  • Somaiah N; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Champiat S; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.
  • Altan M; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Spreafico A; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Rahma O; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Paul EM; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
  • Ahlers CM; Replimune Group Inc, Woburn, Massachusetts, USA.
  • Zhou H; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
  • Struemper H; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
  • Gorman SA; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
  • Watmuff M; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
  • Yablonski KM; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
  • Yanamandra N; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
  • Chisamore MJ; Merck & Co Inc, Kenilworth, New Jersey, USA.
  • Schmidt EV; Merck & Co Inc, Kenilworth, New Jersey, USA.
  • Hoos A; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
  • Marabelle A; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.
  • Weber JS; Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
  • Heymach JV; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J Immunother Cancer ; 11(3)2023 03.
Article em En | MEDLINE | ID: mdl-36927527
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article